Key result
IL-1β promotes endothelial LDL transcytosis via a novel LDLR- and Rab27a-dependent pathway.
In early atherosclerosis, circulating LDLs (low-density lipoproteins) traverse individual endothelial cells by an active process termed transcytosis. The CANTOS trial (Canakinumab Antiinflammatory Thrombosis Outcome Study) treated advanced atherosclerosis using a blocking antibody for IL-1β (interleukin-1β); this significantly reduced cardiovascular events. However, whether IL-1β regulates early disease, particularly LDL transcytosis, remains unknown.
No takes yet. Share an insight, caveat, or question.
Jang et al. (2024) studied Atherosclerosis. IL-1β was evaluated. IL-1β induces LDL transcytosis by a novel pathway involving LDLR and Rab27a.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: